Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn Henry

Showing results (1-10 of 190) with videos related to

Pageof 19
Sort By:
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 14, 2016
The pathway to clinical use of a cancer biomarkerN Lynn Henry
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Endocrine therapy toxicity: management optionsN Lynn Henry
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2015
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerAki Morikawa, N Lynn Henry
Molecular Oncology|February 24, 2012
Cancer biomarkersN Lynn Henry, Daniel F Hayes
Current Oncology Reports|March 3, 2017
Extended Endocrine Therapy: Is 5 Years Enough?Manali A Bhave, N Lynn Henry
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Adjuvant endocrine therapy in premenopausal women with breast cancerKunal C Kadakia, N Lynn Henry
Oncology (Williston Park, N.Y.)|June 24, 2009
Complexities of adjuvant endocrine therapy in young premenopausal womenN Lynn Henry, Jennifer J Griggs
Oncology (Williston Park, N.Y.)|December 18, 2007
Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancerN Lynn Henry, Daniel F Hayes
The Oncologist|June 24, 2006
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancerN Lynn Henry, Daniel F Hayes
Cancer|May 24, 2019
Breast cancer histologic subtypes show excess familial clusteringN Lynn Henry, Lisa A Cannon-Albright
Pageof 19

Showing results (1-10 of 190) with videos related to

Sort By:
Pageof 19
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|July 14, 2016
The pathway to clinical use of a cancer biomarkerN Lynn Henry
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
Endocrine therapy toxicity: management optionsN Lynn Henry
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2015
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerAki Morikawa, N Lynn Henry
Molecular Oncology|February 24, 2012
Cancer biomarkersN Lynn Henry, Daniel F Hayes
Current Oncology Reports|March 3, 2017
Extended Endocrine Therapy: Is 5 Years Enough?Manali A Bhave, N Lynn Henry
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Adjuvant endocrine therapy in premenopausal women with breast cancerKunal C Kadakia, N Lynn Henry
Oncology (Williston Park, N.Y.)|June 24, 2009
Complexities of adjuvant endocrine therapy in young premenopausal womenN Lynn Henry, Jennifer J Griggs
Oncology (Williston Park, N.Y.)|December 18, 2007
Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancerN Lynn Henry, Daniel F Hayes
The Oncologist|June 24, 2006
Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancerN Lynn Henry, Daniel F Hayes
Cancer|May 24, 2019
Breast cancer histologic subtypes show excess familial clusteringN Lynn Henry, Lisa A Cannon-Albright
Pageof 19